Abilify

Drug: Abilify
Company: Bristol-Myers Squibb
Total spend Q1, 2012: $35.9 million
Total spend Q1, 2011: $29.7 million
Watch the TV commercial here >>

While it got itself into trouble early with this atypical antipsychotic, in the long run it has paid off handsomely for Bristol-Myers Squibb ($BMY). Abilify placed third in drugs.com's first-quarter ranking of top selling drugs at $1.34 billion. Pretty impressive since sales in all of last year were $2.8 billion, suggesting that the advertising is paying off. It has not always been smooth sailing on this product. Abilify was the focus of the company's 2007, $515 million settlement agreement with the Justice Department, which said the company targeted sales at dementia patients and adolescents, in whom use was unapproved at the time. Bristol-Myers licenses the drug from Japan's Otsuka Pharmaceutical and has patent protection in the U.S. into 2015.

Abilify
Read more on

Suggested Articles

Sanofi will unload six manufacturing sites and 3,100 employees into a new API production company as it looks for €2 billion in cost savings.

With a new target date approaching for its competitor to Lantus, the FDA has again given Biocon’s insulin manufacturing plant in Malaysia a once over.

Despite outcomes data that left analysts less-than-enthused, Eli Lilly's Trulicity scored the FDA's nod to lower CV risks in a first-ever approval.